(Albany, USA) DelveInsight’s 'JAK Inhibitors Competitive Landscape 2023' report provides comprehensive global coverage of available, marketed, and pipeline JAK inhibitor drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors competitive domain.
Request for Sample report @ https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-competitive-landscape
Key Takeaways from the JAK Inhibitors Pipeline Report
- Over 40+ JAK Inhibitors companies are evaluating 45+ JAK inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the JAK inhibitors market would significantly increase market revenue.
- Leading JAK inhibitor companies working in the market are Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, Geron Corporation, R-Pharm, Almedis LLC, ScienceFiles, Vertex Pharmaceuticals Incorporated, Italfarmaco, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Bristol-Myers Squibb, Cephalon, Karyopharm Therapeutics Inc, and others.
- Promising JAK inhibitor pipeline therapies in various stages of development include PF-06651600, Momelotinib, TD-8236, DZD4205, TD-0903, TD-5202, ATI-2138, CPL409116, Itacitinib, Ruxolitinib, Upadacitinib, Filgotinib, Ivarmacitinib, and others.
- In October 2022, AbbVie announced that the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) had been approved by the US Food and Drug Administration (FDA) for adults with non-radiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation and have had an inadequate response to or are intolerant of one or more tumor necrosis factor (TNF) inhibitors.
- In October 2022, Incyte announced that data from the pivotal Phase III TRuE-V clinical trial program evaluating ruxolitinib cream (OpzeluraTM) 1.5% in patients 12 years of age and older with nonsegmental vitiligo had been published in “The New England Journal of Medicine (NEJM).
JAK Inhibitors Overview
Janus kinase (JAK) inhibitors are small molecules of about 400 Da that can be administered orally. JAKs are phosphotransferases that bind to cytokine receptor intracellular domains and transmit signals to activate immune responses. Many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines are among the cytokines that signal via JAKs (such as erythropoietin). These cytokine receptors communicate via various combinations of four JAKs (JAK1, JAK2, JAK3, and TYK2).
Tofacitinib and baricitinib (and oclacitinib in dogs) are first-generation jakinibs that block more than one JAK and thus inhibit many cytokines; these and other pan-jakinibs are being studied as therapeutic agents for a wide range of autoimmune diseases.
Several JAK inhibitor clinical trials are currently underway, ranging from cancer to autoimmune diseases like psoriasis. Several other JAK inhibitors may be effective in the treatment of multiple disorders in the future.
Find out more about FDA approved JAK inhibitors @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape
JAK Inhibitors Pipeline Analysis: Drug Profile
RINVOQ: AbbVie
RINVOQ, a selective JAK inhibitor discovered and developed by AbbVie scientists, is being studied in a variety of immune-mediated inflammatory diseases. RINVOQ inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy and safety is unknown at this time.
RINVOQ is currently being studied in phase III trials for colitis, giant cell arteritis, and Takayasu arteritis.
Filgotinib: Galapagos
Galapagos’ Filgotinib (200 mg and 100 mg tablets) is approved and marketed in Europe and Japan for the treatment of adults with moderately to severely active RA who have not responded adequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib can be used alone or in conjunction with methotrexate (MTX). Filgotinib was submitted to the European Commission for an expanded indication for the treatment of adults with moderate to severe active ulcerative colitis who had an inadequate response, lost response to, or were intolerant to, conventional therapy or a biologic agent.
JAK Inhibitors Pipeline Drugs mentioned in the report:
| JAK Inhibitors Drugs | Company | Phase | Indication |
| RINVOQ | AbbVie | Pre-registration | Crohn's disease |
| Ritlecitinib | Pfizer | Pre-registration | Alopecia areata |
| Momelotinib | Sierra Oncology | Pre-registration | Myelofibrosis |
| Ruxolitinib | Incyte Corporation/Novartis | Phase III | Cytokine release syndrome; Essential thrombocythaemia; SARS-CoV-2 acute respiratory disease |
| Filgotinib | Galapagos | Phase III | Crohn's disease |
| Itacitinib | Incyte Corporation | Phase III | Graft-versus-host disease |
| Ivarmacitinib | Arcutis Biotherapeutics/Reistone Biopharma | Phase III | Atopic dermatitis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis |
| Golidocitinib | Dizal Pharmaceutical | Phase II | Peripheral T-cell lymphoma |
| Nezulcitinib | Theravance Biopharma | Phase II | Acute lung injury |
| CPL409116 | Celon Pharma | Phase II | Rheumatoid arthritis |
| TD 5202 | Theravance Biopharma | Phase I | Inflammatory bowel diseases |
| ATI-2138 | Aclaris Therapeutics | Phase I | Psoriasis |
Learn more about the JAK inhibitor drugs @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape
Scope of the JAK Inhibitors Competitive Landscape Report
- Coverage: Global
- Key JAK Inhibitors Companies: Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, Geron Corporation, R-Pharm, Almedis LLC, ScienceFiles, Vertex Pharmaceuticals Incorporated, Italfarmaco, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Bristol-Myers Squibb, Cephalon, Karyopharm Therapeutics Inc, and others
- Key JAK Inhibitors Pipeline Therapies: PF-06651600, Momelotinib, TD-8236, DZD4205, TD-0903, TD-5202, ATI-2138, CPL409116, Itacitinib, Ruxolitinib, Upadacitinib, Filgotinib, Ivarmacitinib, and others.
Dive deep for rich insights into JAK inhibitor therapy; visit@ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape
Table of Contents
1. JAK Inhibitors Pipeline Report Introduction
2. JAK Inhibitors Pipeline Report Executive Summary
3. JAK Inhibitors Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. JAK Inhibitors Clinical Trial Therapeutics
6. JAK Inhibitors Pipeline: Late Stage Products (Pre-registration)
7. JAK Inhibitors Pipeline: Late Stage Products (Phase III)
8. JAK Inhibitors Pipeline: Mid Stage Products (Phase II)
9. JAK Inhibitors Pipeline: Early Stage Products (Phase I)
10. JAK Inhibitors Pipeline Therapeutic Assessment
11. Inactive Products in the JAK Inhibitors Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the JAK Inhibitors Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the JAK inhibitors therapeutics assessment, reach out @ https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services
